Noor Wortelboer

Statistics

Publications

Citations

159

H-Index

Active since

2023

Affiliations

Jeroen Bosch Ziekenhuis(Current)

Erasmus University Rotterdam

Netherlands Comprehensive Cancer Organisation

St. Antonius Ziekenhuis

Medisch Centrum Leeuwarden

Noor Wortelboer is an author at Jeroen Bosch Ziekenhuis specializing in cyclin-dependent kinase 4 inhibitors, cyclin-dependent kinase 6 inhibitors, and oncology.

ORCID

Publications per year

2023–2024

Publications

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Nature · 2024 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16

1–2 of 2